{"entity":{"id":"nct04665609","kind":"trial","name":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","aka":[],"tldr":"A phase 3 trial of Thermal ablation in Hepatocellular carcinoma, run by Chinese PLA General Hospital, with a status the registry has not verified recently.","summary":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC is a phase 3 interventional study registered as NCT04665609 by Chinese PLA General Hospital, with 80 participants planned, started 2021-03-05 and due to reach its primary completion in 2022-12-31. Interventions recorded: Anlotinib and TQB2450 solution, TQB2450 solution. Conditions recorded: Hepatocellular Carcinoma, Thermal Ablation, Anlotinib, PDL-1.\n\nLinked to the technology Thermal ablation because the registry's title names it (\"thermal ablation\") and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04665609","url":"https://clinicaltrials.gov/study/NCT04665609"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["thermal-ablation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04665609","phase":"3","setting":"Safety and Effectiveness of Thermal Ablation Combined With Anlotinib and TQB2450 Solution for Advanced Hepatocelualr Carcinoma","sponsor":"Chinese PLA General Hospital","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04665609/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"}]}}